- RecruitingPHASE3
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
This study looks at a new drug combination, avutometinib and defactinib, for low-grade serous ovarian cancer that has come back. It compares this new treatment to standard options to see which works best and is safest for patients.
For: Low Grade Serous Ovarian CancerUnited States · Australia · Belgium - RecruitingPHASE1, PHASE2
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
This study is testing two new drugs, avutometinib and defactinib, alone and with temozolomide, for people with aggressive brain tumours like glioblastoma. It aims to see if they are safe and can shrink tumours, particularly in patients with specific genetic changes.
For: Glioblastoma Multiforme (GBM) · Glioblastoma Multiform (Grade IV Astrocytoma) · Diffuse Hemispheric Glioma, H3 G34-MutantUnited Kingdom